Phibro Animal Health traded at $47.34 this Monday March 9th, decreasing $0.58 or 1.21 percent since the previous trading session. Looking back, over the last four weeks, Phibro Animal Health lost 8.50 percent. Over the last 12 months, its price rose by 103.83 percent. Looking ahead, we forecast Phibro Animal Health to be priced at 46.47 by the end of this quarter and at 42.39 in one year, according to Trading Economics global macro models projections and analysts expectations.
Phibro Animal Health Corporation is a global diversified animal health and mineral nutrition company. The Company operates in three segments, which include Animal Health, Mineral Nutrition and Performance Products. The Company develops, manufactures and markets a range of products for food animals, including poultry, swine, beef and dairy cattle, and aquaculture. The Company sells animal health and mineral nutrition products either directly to integrated poultry, swine and cattle producers or through commercial animal feed manufacturers, wholesalers and distributors. Its Medicated Feed Additives (MFAs) and other business consist of concentrated medicated products, which are administered through animal feeds. The Company's MFAs and other business consists of the production and sale of antibacterials, including Stafac, Terramycin, Neo-Terramycin and Mecadox and anticoccidials, including Nicarb, Aviax, Aviax Plus, Coxistac and amprolium.